Foresee Pharmaceuticals

Foresee Pharmaceuticals is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (TPEx: 6576). Foresees R&D efforts are focused on two key areas, namely its unique Stabilized Injectable Formulation (SIF) long-acting injectable technology with derived drug products targeting specialty markets and secondly, its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresees product portfolio includes late and early-stage programs. CAMCEVI 42 mg, for the treatment of advanced prostate cancer, is now approved in the U.S., Canada, EU, Taiwan and Israel and launched in the U.S. in April 2022. Additionally,...

Pharmaceuticals,rare disease,oncology,neuroscience,urology,pulmonary/respiratory diseases,cardiology/vascular diseases,and biotechnology

Foresee pharmaceuticals operates in the Biotechnology research industry.

Foresee pharmaceuticals's revenue is 11m - 100m

Foresee pharmaceuticals has 11 - 50 employees.